Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious inflammatory and autoimmune diseases. Headquartered in Hayward, California, Anthera’s research and development efforts are centered on targeting key pathways involved in immune dysregulation. The company’s portfolio includes small-molecule and biologic candidates designed to address conditions with significant unmet medical needs.
Among Anthera’s leading product candidates is a spleen tyrosine kinase (SYK) inhibitor being evaluated for immune thrombocytopenia (ITP) and other autoimmune disorders characterized by aberrant B-cell signaling. In parallel, the company has advanced BLISIBIMOD, a selective BAFF-neutralizing peptide, into clinical studies for indications such as IgA nephropathy and systemic lupus erythematosus (SLE). These programs leverage Anthera’s proprietary expertise in immune modulation and its established manufacturing partnerships.
Since its inception, Anthera has conducted multiple Phase 2 and Phase 3 trials across North America, Europe and Asia, collaborating with academic medical centers and patient advocacy groups. The company’s strategic alliances facilitate global trial enrollment and bolster its regulatory strategy, with the goal of achieving timely approvals and broad patient access. Anthera’s business model also contemplates out-licensing opportunities to larger pharmaceutical partners for late-stage development and commercialization.
Anthera is led by a management team with deep experience in biopharmaceutical R&D, regulatory affairs and commercial operations. The board and executive officers bring together expertise from established life science companies, contributing to the company’s disciplined approach to clinical development and corporate governance. Through its targeted pipeline, Anthera aims to deliver new therapies that improve outcomes for patients living with debilitating autoimmune diseases.
AI Generated. May Contain Errors.
